FDA Drug recall D-1556-2014
VIVITROL (naltrexone for extended-release injectable suspension)
- FDA Drug
- Class II
- terminated
- Published 2014-09-03
On 2014-09-03 the FDA classified a Class II recall of VIVITROL (naltrexone for extended-release injectable suspension) by Alkermes, citing customer complaints for failure to deliver the dose.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1556-2014 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2014-03-04 |
| Published | 2014-09-03 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Alkermes |
| Distribution | US |
Product
VIVITROL (naltrexone for extended-release injectable suspension); 380 mg vial NDC 65757-300-01; RX Only Manufactured and marketed by Alkermes, Inc., Waltham, MA 02451.
Reason
Customer complaints for failure to deliver the dose.
Identifiers
| ndc | 65757-300-01 |
|---|---|
| ndc | 65757-302-02 |
| ndc | 65757-304-03 |
| ndc | 65757-301-01 |
| ndc | 65757-303-02 |
| ndc | 65757-305-03 |
| code_info | Batch Number: 412-3732AA; expiration date 07/2016 (NDC# 65757-302-02; Kit Pacaging Lot Number: 2013-021; expiration date 07/2016 (NDC# 65757-300-01. |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1556-2014%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.